Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

Research output: Contribution to journalComment/Letter to the editorAcademic

Original languageEnglish
Pages (from-to)822-823
JournalMultiple Sclerosis Journal
Volume24
Issue number6
DOIs
Publication statusPublished - 2018

Cite this

@article{ad6df1e2d2e442e695cd3da9bb2bcc98,
title = "Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”",
author = "{van Kempen}, {Zo{\'e} L. E.} and Theo Rispens and Joep Killestein",
year = "2018",
doi = "10.1177/1352458517734073",
language = "English",
volume = "24",
pages = "822--823",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Response to “Letter to the editor on the paper: The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing”

AU - van Kempen, Zoé L. E.

AU - Rispens, Theo

AU - Killestein, Joep

PY - 2018

Y1 - 2018

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85043329197&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/28990853

U2 - 10.1177/1352458517734073

DO - 10.1177/1352458517734073

M3 - Comment/Letter to the editor

VL - 24

SP - 822

EP - 823

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 6

ER -